iiinova — where your digital self keeps evolving

Reposted by Solomon Rotimi, PhD

Technology in Cancer Research & Treatment (IF 2.8) @tcrtcancer.bsky.social · 24/04/2025

New research in TCRT @tcrtcancer.bsky.social identifies pathogenic BRCA1/2 variants in Nigerian breast cancer patients, highlighting the need for genetic screening. bit.ly/4m3eX2L; bit.ly/42uWdBr @solomonrotimi.bsky.social @journals.sagepub.com #BreastCancer #Genetics #CancerResearch

043

Solomon Rotimi, PhD @solomonrotimi.bsky.social · 01/04/2025

Want to collaborate on the next study? Want to join a cancer genomics-focused training cohort? Looking for guidance on launching local genomics study or precision oncology intiatives? Please reach out. Follow @iccareforblackmen.bsky.social and me. We’re open to partnerships and mentorships.

010

Solomon Rotimi, PhD @solomonrotimi.bsky.social · 01/04/2025

This is a call to: • Researchers: Let’s build multi-site African genomics cohorts • Clinicians: Let’s move toward point-of-care genetic testing • Funders: Invest in local genomic capacity • Students: Join our mentorship training tracks

100

Solomon Rotimi, PhD @solomonrotimi.bsky.social · 01/04/2025

This is how we build local capacity. Enough of the dependency. It is also a testament to the commitment of CaPTC and @iccareforblackmen.bsky.social to developing local capacity and discouraging vampire science.

100

Solomon Rotimi, PhD @solomonrotimi.bsky.social · 01/04/2025

Many thanks to Nigerian iccareforblackmen.bsky.social, and CaPTC investigators and our outstanding graduate students and early-stage investigators in our group

iccareforblackmen.bsky.social

100

Solomon Rotimi, PhD @solomonrotimi.bsky.social · 01/04/2025

All 3 pathogenic mutations were found in women with triple-negative breast cancer, with family history of cancer. BRCA1 mutations were found in women below 40yr of age. The distinct haplotypes show that ancestry-specific variants matter and that African populations can’t rely on Eurocentric panels.

100

Solomon Rotimi, PhD @solomonrotimi.bsky.social · 01/04/2025

Using next generation sequencing approach we identified: • 3 pathogenic BRCA1/2 mutations • 97 benign variants • 18 variants of unknown significance • Distinct Nigerian haplotypes

100

Solomon Rotimi, PhD @solomonrotimi.bsky.social · 01/04/2025

With a population of over 200 million and over 100,000 newly diagnosed cancers annually, this work demonstrates the competency of the local capacity, resources, and infrastructure to meet the precision oncology needs of our patients.

110

Solomon Rotimi, PhD @solomonrotimi.bsky.social · 01/04/2025

This publication is our bold move to change the paradigm and reduced the barrier to inequities in access to precision oncology care.

100

Solomon Rotimi, PhD @solomonrotimi.bsky.social · 01/04/2025

Yes, other cancer genomics studies exist. But here’s the game-changer: To our knowledge, this is the first study conducted entirely in Nigeria—from sample collection to sequencing to variant calling to haplotype mapping. No foreign sequencing. No outsourced bioinformatics.

110

Solomon Rotimi, PhD @solomonrotimi.bsky.social · 01/04/2025

But this is bigger than data or just another study—this is a demonstration of African cancer genomic independence required for achieving equity in global precision oncology and cancer control.

100

Solomon Rotimi, PhD @solomonrotimi.bsky.social · 01/04/2025

EXCITING ANNOUNCEMENT Our study on BRCA1/2 variants in Nigerian breast cancer patients is now accepted in Technology in Cancer Research & Treatment @tcrtcancer.bsky.social #BRCA #BreastCancer #healthEquity

120